HAI-ROBOTICS
14.12.2021 14:22:13 CET | Business Wire | Press release
HAI ROBOTICS , a global leader in Autonomous Case-handling Robotics (ACR) system for warehouse fulfillment, marked a milestone for its solution of HAIPORT-powered Workstation -- with over 100 sets in operation globally since the product was launched one year ago. The solution has enormously improved order fulfillment efficiency for its customers who were pressured to update their warehousing facilities with higher throughput capacity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005725/en/
HAIPORT is an automatic loading and unloading machine that can be docked with HAI ROBOTICS’ autonomous case-handling robots and conveyor workstations.
At a HAIPORT-powered Workstation, multiple loads of totes or cartons are unloaded from the HAIPICK robots at the HAIPORT loader, then transferred onto the conveyor belts for sorting per system orders and moved to the HAIPORT unloader, where they were fetched by robots for the next round of order processing.
The collaboration between HAIPICK robots, HAIPORT, and conveyor belt allows one-stop case-handling from in-bounds to out-bounds. The solution boasts obvious advantages by increasing the throughput of a warehouse.
With case loading and unloading being processed simultaneously at the two sides of a HAIPORT, a single workstation can be expected to handle up to 900 cases per hour, far exceeding that of manual handling. The speed is 16 times faster than the robot-to-conveyor belt transport.
The speed - four to eight cases being loaded in 3 seconds and unloaded in 5s - promises higher case-handling capacity. A single robot’s efficiency can be improved by 30% compared with manual loading/unloading.
Designed to realize direct interaction between HAIPICK robot and conveyor belt, HAIPORT-powered workstation guarantees higher loading and unloading speeds with least human intervention, increasing manual picking efficiency up to 3 times. The use of the workstation can free warehouse staff from tedious manual labor so that they can focus on more important tasks.
Armed with HAI ROBOTICS’ software platform as well as the multi-sensor technology that can monitor a robot’s movement, the workstation can accurately judge if a particular case of goods should be delivered to a workstation or not. Its modular design also grants scalability and flexibility when automating a warehouse. It can be customized and adapted for different uses based on the customer’s requirements. As a result, 30% fewer robots are required if a HAIPORT-powered Workstation is deployed in a warehouse.
HAIPORT-powered workstation has been certified by CE and ETL in compliance with the safety standards for Europe and US markets, respectively. The certifications also evidence that HAI ROBOTICS has been implementing stringent quality control for its products along its own supply chain, in product design and production.
Jeff Zheng, R&D Director at HAI ROBOTICS, said, “HAIPORT-powered Workstation offers an innovative solution for warehousing automation and provides a new way of human-machine interaction. It helps not only increase operational efficiency, but also reduce costs and deliver better ROI. We’re committed to delivering more value to our customers and making their investments worthwhile.”
Thanks to its flexibility, HAIPORT-powered Workstation is suitable for extensive storage scenarios in which medium and small-sized cases are used, such as raw materials, small electronics, apparels, medicine, retails and 3PL industries that have large number of SKUs and demand high order fulfillment efficiency in peak hours with surging e-commerce demands.
About HAI ROBOTICS
HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) system, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.
The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005725/en/
Link:
Social Media:
https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
